Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Agno Pharma Acquires Lubrizol Particle Sciences | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Agno Pharma Acquires Lubrizol Particle Sciences

Expands capability and capacity to extend its drug product formulation and clinical manufacturing services.

By: Anthony Vecchione

Agno Pharma, a global pharmaceutical CDMO, acquired Lubrizol Particle Sciences Inc. The acquisition includes the drug product formulation technology behind the Particle Sciences Inc. business as well as the Bethlehem, PA, development, and manufacturing site which employs approximately 65 employees.

Particle Sciences specializes in preclinical and clinical stage drug product formulation and offers a comprehensive suite of supporting services, including analytic, bioanalytic, physical characterization, and manufacturing. The company has expertise in dealing with poorly soluble and highly potent compounds in both sterile and non-sterile environments.

The acquisition of Particle Sciences will provide Agno with expanded capability and capacity to extend its drug product formulation and clinical manufacturing services to its customers globally. Agno plans to further invest in clinical scale manufacturing services from sterile liquid manufacturing and filling services to micronization of sterile powder filling capabilities.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics